Showing results (141-150 of 223) with videos related to

Sort By:
Pageof 23
Archives of Pathology & Laboratory Medicine|August 7, 2024
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast CancerJosef Rüschoff, Alexander Penner, Ian O Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumorsMaria Martinez-Garcia, Udai Banerji, Joan Albanell, et al.
NPJ Breast Cancer|June 20, 2025
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trialJoan Albanell, Angelo Gámez Pozo, Carlos L Arteaga, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 12, 2025
PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significanceLuis Fernando García, Esther Conde, Susana Hernandez, et al.
Epigenetics|December 9, 2014
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapyOlga Pernía, Cristobal Belda-Iniesta, Veronica Pulido, et al.
Breast Cancer Research and Treatment|January 5, 2019
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 studyAlberto Ocana, Marta Gil-Martin, Silvia Antolín, et al.
International Journal of Molecular Sciences|June 9, 2016
MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal CancerCristina Caramés, Ion Cristobal, Víctor Moreno, et al.
Molecular Oncology|September 11, 2024
Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitorsAnna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, et al.
Journal of the National Cancer Institute|September 18, 2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone MetastasisMilica Pavlovic, Anna Arnal-Estapé, Federico Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicinFederico Rojo, Irene González-Navarrete, Rafael Bragado, et al.
Pageof 23